Table 2.
Demographic and baseline characteristics.
| Parameter | FAS population | ||
|---|---|---|---|
| IQP-AE-103 LD (N=35) | IQP-AE-103 HD (N=35) | Placebo (N=31) | |
| Gender | |||
| Men | 8 (22.9%) | 9 (25.7%) | 9 (29%) |
| Women | 27 (77.1%) | 26 (74.3%) | 22 (71%) |
| Mean age (years) | 46.8 ± 12.3 | 48.7 ± 12.8 | 46.7 ± 12.2 |
| Age group | |||
| 18–40 years | 9 (25.7%) | 9 (25.7%) | 11 (35.5%) |
| 41–65 years | 26 (74.3%) | 26 (74.3%) | 20 (64.5%) |
| Height (cm) | 169.5 ± 10.6 | 168.8 ± 8.9 | 168.7 ± 11.0 |
| Body weight (kg) | 84.42 ± 14.89 | 84.04 ± 10.56 | 86.77 ± 15.27 |
| BMI (kg/m2) | 29.15 ± 2.17 | 29.44 ± 2.31 | 30.25 ± 2.59 |
| Energy requirement (kcal) | 2193.7 ± 473.9 | 2158.7 ± 328.0 | 2230.2 ± 450.6 |
| Waist circumference (cm) | 102.7 ± 10.0 | 100.9 ± 7.5 | 104.7 ± 11.4 |
| Hip circumference (cm) | 107.1 ± 7.8 | 106.9 ± 7.1 | 108.5 ± 6.9 |
| Body fat mass (kg) | 30.90 ± 6.81 | 30.77 ± 6.51 | 31.44 ± 7.34 |
| Fat-free mass (kg) | 53.52 ± 11.98 | 53.29 ± 9.11 | 55.33 ± 13.27 |
All data are presented as mean ± s.d. No significant difference was found between groups for all variables. FAS = full analysis set; LD = low dose; HD = high dose.